TY - JOUR T1 - Seek COVER: Development and validation of a personalized risk calculator for COVID-19 outcomes in an international network JF - medRxiv DO - 10.1101/2020.05.26.20112649 SP - 2020.05.26.20112649 AU - Ross D. Williams AU - Aniek F. Markus AU - Cynthia Yang AU - Talita Duarte Salles AU - Thomas Falconer AU - Jitendra Jonnagaddala AU - Chungsoo Kim AU - Yeunsook Rho AU - Andrew Williams AU - Min Ho An AU - María Aragón AU - Carlos Areia AU - Edward Burn AU - Young Hwa Choi AU - Iannis Drakos AU - Maria Tereza Fernandes Abrahão AU - Sergio Fernández-Bertolín AU - George Hripcsak AU - Benjamin Skov Kaas-Hansen AU - Prasanna L Kandukuri AU - Kristin Kostka AU - Siaw-Teng Liaw AU - Rae Woong Park AU - Nicole Pratt AU - Gerardo Machnicki AU - Daniel Morales AU - Fredrik Nyberg AU - Albert Prats-Uribe AU - Gowtham Rao AU - Christian G. Reich AU - Marcela Rivera AU - Tom Seinen AU - Azza Shoaibi AU - Matthew E Spotnitz AU - Ewout W. Steyerberg AU - Marc A. Suchard AU - Seng Chan You AU - Lin Zhang AU - Lili Zhou AU - Patrick B. Ryan AU - Daniel Prieto-Alhambra AU - Jenna M. Reps AU - Peter R. Rijnbeek Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/27/2020.05.26.20112649.abstract N2 - Importance COVID-19 is causing high mortality worldwide. Developing models to quantify the risk of poor outcomes in infected patients could help develop strategies to shield the most vulnerable during de-confinement.Objective To develop and externally validate COVID-19 Estimated Risk (COVER) scores that quantify a patient’s risk of hospital admission (COVER-H), requiring intensive services (COVER-I), or fatality (COVER-F) in the 30-days following COVID-19 diagnosis.Design Multinational, distributed network cohorts.Setting We analyzed a federated network of electronic medical records and administrative claims data from 13 data sources and 6 countries, mapped to a common data model.Participants Model development used a patient population consisting of >2 million patients with a general practice (GP), emergency room (ER), or outpatient (OP) visit with diagnosed influenza or flu-like symptoms any time prior to 2020. The model was validated on patients with a GP, ER, or OP visit in 2020 with a confirmed or suspected COVID-19 diagnosis across four databases from South Korea, Spain and the United States.Outcomes Age, sex, historical conditions, and drug use prior to index date were considered as candidate predictors. Outcomes included i) hospitalization with pneumonia, ii) hospitalization with pneumonia requiring intensive services or death, and iii) death in the 30 days after index date.Results Overall, 43,061 COVID-19 patients were included for model validation, after initial model development and validation using 6,869,127 patients with influenza or flu-like symptoms. We identified 7 predictors (history of cancer, chronic obstructive pulmonary disease, diabetes, heart disease, hypertension, hyperlipidemia, and kidney disease) which combined with age and sex could discriminate which patients would experience any of our three outcomes. The models achieved high performance in influenza. When transported to COVID-19 cohorts, the AUC ranges were, COVER-H: 0.73-0.81, COVER-I: 0.73-0.91, and COVER-F: 0.82-0.90. Calibration was overall acceptable, with overestimated risk in the most elderly and highest risk strata.Conclusions and relevance A 9-predictor model performs well for COVID-19 patients for predicting hospitalization, intensive services and death. The models could aid in providing reassurance for low risk patients and shield high risk patients from COVID-19 during de-confinement to reduce the virus’ impact on morbidity and mortality.Key Points QuestionCan we, by combining socio-demographics and medical history, identify people at high risk of severe forms of disease were they to contract COVID-19 infection?FindingsThe COVID-19 Estimated Risk (COVER) models demonstrated good discrimination and calibration in predicting hospitalization, intensive services, and death for patients with COVID-19, and were successfully applied across populations in US, Europe and Asia.MeaningPersonalized risk predictions for COVID-19 outcomes are possible and can be used to inform individual behavioural choices and help design shielding strategies during de-confinement.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project has received support from the European Health Data and Evidence Network (EHDEN) project. EHDEN received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This project is funded by the Health Department from the Generalitat de Catalunya with a grant for research projects on SARS-CoV-2 and COVID-19 disease organized by the Direcció General de Recerca i Innovació en Salut. The University of Oxford received a grant related to this work from the Bill & Melinda Gates Foundation (Investment ID INV-016201), and partial support from the UK National Institute for Health Research (NIHR) Oxford Biomedical Research Centre. DPA is funded through a NIHR Senior Research Fellowship (Grant number SRF-2018-11-ST2-004). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. AP-U is supported by Fundacion Alfonso Martin Escudero and the Medical Research Council (grant numbers MR/K501256/1, MR/N013468/1). BSKH is funded through Innovation Fund Denmark (5153-00002B) and the Novo Nordisk Foundation (NNF14CC0001). This work was also supported by the Bio Industrial Strategic Technology Development Program (20001234) funded by the Ministry of Trade, Industry & Energy (MOTIE, Korea) and a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea [grant number: HI16C0992]. This project is part funded by the UNSW RIS grant. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All databases obtained IRB approval or used deidentified data that was considered exempt from IRB approval. Informed consent was not necessary at any site.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is not publicly available due to patient privacy concerns. ER -